Ensoma
Genetic medicines company developing in vivo engineered cell therapies using its Engenious platform to treat genetic diseases, including X-linked chronic granulomatous disease (X-CGD).
Notes
Ensoma is a genetic medicines company headquartered in Boston, Massachusetts, focused on developing in vivo engineered cell therapies for genetic diseases. The company's Engenious platform enables direct in vivo genetic modification of cells, potentially offering advantages over traditional ex vivo gene therapy approaches.
Ensoma's lead program, EN-374, is in Phase 1/2 clinical trials for the treatment of X-linked chronic granulomatous disease (X-CGD), a rare primary immunodeficiency. The company's approach aims to modify stem cells directly in the patient's body, potentially eliminating the need for cell collection, ex vivo manipulation, and reinfusion.
Team
- Paula Cannon, Ph.D. - Co-founder & Scientific Advisor
- Leadership team available on company website
Additional Research Findings
- Founded in 2020
- Portfolio company of 5AM Ventures
- Headquarters: Boston, Massachusetts
- Engenious platform for in vivo genetic medicine
- Lead program: EN-374 for X-CGD
- Phase 1/2 clinical trial ongoing
- Focus on rare genetic diseases
- In vivo engineered cell therapy approach
- Raised significant venture funding
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| 5AM Ventures | Menlo Park, USA | biotech-focused | seedseries-a+1 | 8 |